

**New York State Department of Health
Wadsworth Center**

Proficiency Testing Program

17-Jan-07

**DIAGNOSTIC IMMUNOLOGY &
HUMAN IMMUNODEFICIENCY VIRUS
SUMMARY ANALYSIS**

**Proficiency Test Event
17-Jan-07**

**Diagnostic Immunology & Human Immunodeficiency Virus
Summary Report**

Steven Bush M.S., Wendy Archinal Ph.D., and Susan Wong Ph.D.

Table of Contents

Review of Grading Policy	Page 3
Determination of Acceptable Responses	Page 4
Qualitative / Quantitative Test Analytes	Page 5 - 28
Antinuclear Ab	Page 5 - 6
Antistreptolysin O	Page 7 - 9
Cytomegalovirus Ab	Page 10
Hepatitis B Core Ab	Page 11
Hepatitis B Surface Ag	Page 12
Hepatitis Be Ag	Page 13
Hepatitis C Ab	Page 13
HIV Ab Screening/ Confirmation	Page 14
HIV p24 Ag	Page 14
HTLV1 Ab	Page 15
Infectious Mononucleosis	Page 16 - 17
Lyme Disease (<u>Borrelia burgdorferi</u>) Ab	Page 18 - 19
Rheumatoid Factor	Page 20 - 22
Rubella IgG Ab	Page 23 - 24
Rubella IgM	Page 25
Syphilis-Reagin Ab	Page 26 - 27
Syphilis-Treponemal Ab	Page 28
Quantitative Test Analytes	Page 29 - 30
Alpha-1 Antitrypsin	Page 29
Complement C'3	Page 29
Complement C'4	Page 29
Immunoglobulin A	Page 30
Immunoglobulin E	Page 30
Immunoglobulin G	Page 30
Immunoglobulin M	Page 30
Acceptable Responses	Page 31 - 32

The data summarized in this report were tabulated from test results and accompanying information submitted by laboratories that participated in the January 17, 2007 Diagnostic Immunology and Human Immunodeficiency Virus proficiency test events. Participants are encouraged to review the data and to compare results and test kit performances.

Laboratories were evaluated on the basis of their responses for each analyte and on overall performance for all the analytes tested in the permit category. Appropriate responses were determined by participant consensus requiring 80% agreement in each test.

Qualitative/quantitative results were graded in relation to results given by participants for specific test kits. When the number of participants that used a specific test kit was less than 10, results were graded considering results given for the method used. Target values and acceptable ranges were determined as indicated in Page 5.

Grading Criteria:

- ⊕ When both qualitative and quantitative results were reported ten points were deducted for each incorrect result. When only qualitative OR quantitative results were reported twenty points were deducted for each incorrect result.
- ⊕ For **Diagnostic Services** failure to attain an overall testing score of at least 80% is unsatisfactory performance
- ⊕ For **Donor Services** failure to attain an overall testing score of 100% is unsatisfactory
- ⊕ For **HIV** failure to attain an overall testing score of 100% is unsatisfactory performance.
- ⊕ Laboratories failing two out of three consecutive proficiency test events for an analyte or for the permit category will fail the proficiency testing program for the analyte or for the permit category and may be required to cease patient testing for that analyte/category.

Summary Tables

Test kit manufacturer names are in *italics*. In some tables, test kits are grouped under test methods shown in bold letters. In all tables, test methods and test kit manufacturer names are listed in alphabetic order. Only the testing systems used by 10 or more laboratories are listed in this report.

For qualitative tests, results are summarized as the number of laboratories that reported a test sample as reactive to the number that reported it as non-reactive. In addition, where test results depend on a quantitative value (e.g. titer, IU/ml) the values reported are given in separate tables. They are expressed, where applicable, as the Mean \pm S.D. when ten or more laboratories reported data.

For quantitative tests, values reported variously as mg/dl, IU/ml, etc. are given as the Mean \pm S.D. when ten or more laboratories reported results. Titers are given as endpoint titers.

Disclaimer

The use of brand and/or trade names in this report does not constitute an endorsement of the products on the part of the Wadsworth Center or the New York State Department of Health.

Determination of Acceptable Responses

Analyte or Test	Criteria
Alpha-1 Antitrypsin	Target value \pm 3 S.D.
Antinuclear Antibody	Target value \pm 2 dilutions or positive or negative
Antistreptolysin O	Target value \pm 2 dilutions or Target value \pm 3 S.D. or positive or negative
Complement C'3, C'4	Target value \pm 3 S.D.
Cytomegalovirus Antibody	Reactive / nonreactive
Hepatitis (HbsAg, anti-HBc, HBeAg, and HCAb)	Reactive / nonreactive
HIV 1 Ab, Ag	Reactive / nonreactive
HTLV 1 Ab (EIA Ab, WB)	Reactive / nonreactive
Lyme Disease Ab, WB IgG, IgM	Reactive / nonreactive
Immunoglobulin A, E, M	Target value \pm 3 S.D.
Immunoglobulin G	Target value \pm 25 %
Infectious Mononucleosis	Target value \pm 2 dilutions or positive or negative
Rheumatoid Factor	Target value \pm 2 dilutions or Target value \pm 3 S.D. or positive or negative
Rubella Ab, IgM	Target value \pm 2 dilutions or Target value \pm 3 S.D. or positive or negative or Immune or nonimmune
Syphilis Reagin Antibody	Target value \pm 1 dilution
Syphilis Treponemal Antibody	Reactive / nonreactive

Antinuclear Antibody

Participant Results/ Sample Number																					
R = Reactive/ Positive; N = Non-Reactive/ Negative																					
Method	No. Labs	46 N				47 N				48 N				49 R				50 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
EIA	47	47	100%	0	0%	47	100%	0	0%	47	100%	0	0%	3	6%	44	94%	47	100%	0	0%
<i>Diamedix</i>	12	12	100%		0%	12	100%		0%	12	100%		0%		0%	12	100%	12	100%		0%
<i>Others</i>	35	35	100%		0%	35	100%		0%	35	100%		0%	3	9%	32	91%	35	100%		0%
IFA	82	81	99%	1	1%	82	100%	0	0%	82	100%	0	0%	0	0%	82	100%	82	100%	0	0%
<i>Bio-Rad</i>	26	26	100%		0%	26	100%		0%	26	100%		0%		0%	26	100%	26	100%		0%
<i>The Binding Site</i>	11	11	100%		0%	11	100%		0%	11	100%		0%		0%	11	100%	11	100%		0%
<i>Wampole/Zeus</i>	22	22	100%		0%	22	100%		0%	22	100%		0%		0%	22	100%	22	100%		0%
<i>Others</i>	23	22	96%	1	4%	23	100%		0%	23	100%		0%		0%	23	100%	23	100%		0%
Other Methods	13	13	100%		0%	13	100%		0%	13	100%		0%		0%	13	100%	12	92%	1	8%
Analyte Total	142	141	99%	1	1%	142	100%	0	0%	142	100%	0	0%	3	2%	139	98%	141	99%	1	1%

Note: Of the 92 laboratories reporting staining patterns: 29% found test sample 49 to stain speckled, 35% found sample 49 to stain nucleolar, and 36% found sample 49 to stain Homogenous. Several labs reported more than one staining pattern for the sample, we were only able to record the first pattern listed on the result form. The reporting of a staining pattern here is for informational purposes only and is not used for grading.

Antinuclear Antibody

The number of laboratories that reported titers is listed for positive test sample 49. Only testing systems with 10 or more laboratories reporting titers are listed in this table.

Method <i>Manufacturer</i>	No. Labs	Sample 49							
		40	80	160	320	640	1280	2560	5120
IFA									
<i>Bio-Rad</i>	26		3	8	9	5			
<i>Wampole/ Zeus</i>	18		4	4	7	3	1		
<i>The Binding site</i>	11		1	1	6	2	1		

Note: The number of labs reporting specific titers may not add up to the total number of labs for that system because some labs are not reporting endpoint titers.

Antistreptolysin O

		Participant Results/ Sample Number																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative																			
Method	No. Labs	16 N				17 N				18 R				19 N				20 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
Latex Agglutination	83	83	100%	0	0%	83	100%	0	0%	0	0%	83	100%	83	100%	0	0%	83	100%	0	0%
<i>Behring</i>	19	19	100%		0%	19	100%		0%		0%	19	100%	19	100%		0%	19	100%		0%
<i>Fisher</i>	26	26	100%		0%	26	100%		0%		0%	26	100%	26	100%		0%	26	100%		0%
<i>Remel</i>	15	15	100%		0%	15	100%		0%		0%	15	100%	15	100%		0%	15	100%		0%
<i>Others</i>	23	23	100%		0%	23	100%		0%		0%	23	100%	23	100%		0%	23	100%		0%
Nephelometry	27	27	100%	0	0%	27	100%	0	0%	0	0%	27	100%	27	100%	0	0%	27	100%	0	0%
<i>Beckman</i>	13	13	100%		0%	13	100%		0%		0%	13	100%	13	100%		0%	13	100%		0%
<i>Behring</i>	14	14	100%		0%	14	100%		0%		0%	14	100%	14	100%		0%	14	100%		0%
Turbidimetry	21	21	100%	0	0%	21	100%	0	0%	0	0%	21	100%	21	100%	0	0%	21	100%	0	0%
<i>Roche Diagnostics</i>	13	13	100%		0%	13	100%		0%		0%	13	100%	13	100%		0%	13	100%		0%
<i>Others</i>	8	8	100%		0%	8	100%		0%		0%	8	100%	8	100%		0%	8	100%		0%
Other Methods	11	11	100%		0%	11	100%		0%		0%	11	100%	10	91%	1	9%	11	100%		0%
Analyte Total	142	142	100%	0	0%	142	100%	0	0%	0	0%	142	100%	141	99%	1	1%	142	100%	0	0%

Antistreptolysin O Latex Agglutination Procedures

The number of laboratories that reported titers is listed for positive test sample 18. Only testing systems with 10 or more laboratories reporting titers are listed in this table.

Method <i>Manufacturer</i>	No. Labs	Sample 18 Titers					
		200	400	800	1600	3200	6400
<i>Dade Behring</i>	17		7	6			1
<i>Fisher</i>	16	3	11	1			
<i>Remel</i>	12		8	3	1		

Note: The number of labs reporting specific titers may not add up to the total number of labs for that system because some labs are not reporting endpoint titers.

Antistreptolysin O

Results are summarized for positive test sample 18. The Mean values \pm S.D. are given where 10 or more laboratories reported quantitative results. Outlier values are omitted.

Method	Manufacturer	No. Labs	IU/ml Sample 18
Nephelometry			
	<i>Dade Behring Neph.</i>	14	815 \pm 60
Turbidimetry			
	<i>Roche Diagnostics Cobas</i>	11	734 \pm 56

Cytomegalovirus Antibody

Participant Results/ Sample Number																					
R = Reactive/ Positive; N = Non-Reactive/ Negative																					
Method	No. Labs	11 N				12 N				13 N				14 R				15 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
EIA	40	40	100%	0	0%	40	100%	0	0%	40	100%	0	0%	0	0%	40	100%	40	100%	0	0%
<i>Wampole /Zeus</i>	18	18	100%		0%	18	100%		0%	18	100%		0%		0%	18	100%	18	100%		0%
<i>Others</i>	22	22	100%		0%	22	100%		0%	22	100%		0%		0%	22	100%	22	100%		0%
ELFA	21	21	100%	0	0%	21	100%	0	0%	21	100%	0	0%	0	0%	21	100%	20	95%	1	5%
<i>bioMérieux Vidas</i>	21	21	100%		0%	21	100%		0%	21	100%		0%		0%	21	100%	20	95%	1	5%
Chemiluminescence	14	14	100%	0	0%	14	100%	0	0%	14	100%	0	0%	0	0%	14	100%	14	100%	0	0%
<i>Diagnostic Products</i>	14	14	100%		0%	14	100%		0%	14	100%		0%		0%	14	100%	14	100%		0%
Hemagglutination	11	11	100%	0	0%	11	100%	0	0%	11	100%	0	0%	0	0%	11	100%	11	100%	0	0%
<i>Olympus</i>	11	11	100%		0%	11	100%		0%	11	100%		0%		0%	11	100%	11	100%		0%
Other Methods	11	11	100%		0%	11	100%		0%	11	100%		0%		0%	11	100%	11	100%		0%
Analyte Total	97	97	100%	0	0%	97	100%	0	0%	97	100%	0	0%	0	0%	97	100%	96	99%	1	1%

Hepatitis B Core Antibody

Participant Results/ Sample Number																					
R = Reactive/ Positive; N = Non-Reactive/ Negative																					
Method	No. Labs	6 R				7 R				8 N				9 N				10 N			
		Manufacturer	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R
Chemiluminescence	85	0	0%	85	100%	2	2%	83	98%	84	99%	1	1%	85	100%	0	0%	84	99%	0	0%
<i>Abbott</i>	10		0%	10	100%		0%	10	100%	10	100%		0%	10	100%		0%	10	100%		0%
<i>Bayer</i>	25		0%	25	100%	1	4%	24	96%	24	96%	1	4%	25	100%		0%	25	100%		0%
<i>Diagnostic Products</i> ¹	25		0%	25	100%	1	4%	24	96%	25	100%		0%	25	100%		0%	24	96%		0%
<i>Other</i>	25		0%	25	100%		0%	25	100%	25	100%		0%	25	100%		0%	25	100%		0%
EIA	72	0	0%	72	100%	0	0%	72	100%	72	100%	0	0%	72	100%	0	0%	72	100%	0	0%
<i>Abbott</i>	56		0%	56	100%		0%	56	100%	56	100%		0%	56	100%		0%	56	100%		0%
<i>DiaSorin</i>	11		0%	11	100%		0%	11	100%	11	100%		0%	11	100%		0%	11	100%		0%
<i>Other</i>	5		0%	5	100%		0%	5	100%	5	100%		0%	5	100%		0%	5	100%		0%
Other Methods	2		0%	2	100%		0%	2	100%	2	100%		0%	2	100%		0%	2	100%		0%
Analyte Total	159	0	0%	159	100%	2	1%	157	99%	158	99%	1	1%	159	100%	0	0%	158	99%	0	0%

¹ One laboratory reported a result of equivocal/indeterminate on sample #10.

Hepatitis B Surface Antigen

		Participant Results/ Sample Number																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative																			
Method	No. Labs	6 R				7 N				8 N				9 N				10 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
Chemiluminescence	98	0	0%	98	100%	91	93%	6	6%	97	99%	1	1%	98	100%	0	0%	98	100%	0	0%
<i>Bayer</i>	30		0%	30	100%	29	97%	1	3%	29	97%	1	3%	30	100%		0%	30	100%		0%
<i>Diagnostic Products</i>	28		0%	28	100%	26	93%	2	7%	28	100%		0%	28	100%		0%	28	100%		0%
<i>Ortho</i> ¹	31		0%	31	100%	27	87%	3	10%	31	100%		0%	31	100%		0%	31	100%		0%
<i>Other</i>	9		0%	9	100%	9	100%		0%	9	100%		0%	9	100%		0%	9	100%		0%
EIA	100	0	0%	100	100%	97	97%	3	3%	100	100%	0	0%	100	100%	0	0%	100	100%	0	0%
<i>Abbott</i>	59		0%	59	100%	59	100%		0%	59	100%		0%	59	100%		0%	59	100%		0%
<i>Bio-Rad</i>	11		0%	11	100%	11	100%		0%	11	100%		0%	11	100%		0%	11	100%		0%
<i>Roche</i>	11		0%	11	100%	11	100%		0%	11	100%		0%	11	100%		0%	11	100%		0%
<i>Abbott AxSYM (MEIA)</i>	10		0%	10	100%	7	70%	3	30%	10	100%		0%	10	100%		0%	10	100%		0%
<i>Other</i>	9		0%	9	100%	9	100%		0%	9	100%		0%	9	100%		0%	9	100%		0%
Other Methods	6		0%	6	100%	6	100%		0%	6	100%		0%	6	100%		0%	6	100%		0%
Analyte Total	204	0	0%	204	100%	194	95%	9	4%	203	100%	1	0%	204	100%	0	0%	204	100%	0	0%

¹ One laboratory reported a result of equivocal/indeterminate for sample #7.

Hepatitis Be Antigen

Participant Results/ Sample Number																					
R = Reactive/ Positive; N = Non-Reactive/ Negative																					
Method	No. Labs	66 N				67 R				68 N				69 N				70 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
EIA	28	28	100%	0	0%	0	0%	28	100%	28	100%	0	0%	28	100%	0	0%	28	100%	0	0%
<i>DiaSorin</i>	28	28	100%		0%		0%	28	100%	28	100%		0%	28	100%		0%	28	100%		0%
Other Methods	5	5	100%		0%		0%	5	100%	5	100%		0%	5	100%		0%	5	100%		0%
Analyte Total	33	33	100%	0	0%	0	0%	33	100%	33	100%	0	0%	33	100%	0	0%	33	100%	0	0%

Hepatitis C Antibody

Participant Results/ Sample Number																					
R = Reactive/ Positive; N = Non-Reactive/ Negative																					
Method	No. Labs	71 N				72 N				73 R				74 N				75 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
Chemiluminescence	69	69	100%	0	0%	68	99%	1	1%	1	1%	68	99%	69	100%	0	0%	69	100%	0	0%
<i>Bayer</i>	33	33	100%		0%	33	100%		0%		0%	33	100%	33	100%		0%	33	100%		0%
<i>Ortho</i>	32	32	100%		0%	32	100%		0%		0%	32	100%	32	100%		0%	32	100%		0%
<i>Other</i>	4	4	100%		0%	3	75%	1	25%	1	25%	3	75%	4	100%		0%	4	100%		0%
EIA	84	84	100%	0	0%	84	100%	0	0%	0	0%	84	100%	84	100%	0	0%	84	100%	0	0%
<i>Abbott</i>	58	58	100%		0%	58	100%		0%		0%	58	100%	58	100%		0%	58	100%		0%
<i>Ortho</i>	26	26	100%		0%	26	100%		0%		0%	26	100%	26	100%		0%	26	100%		0%
MEIA	18	18	100%	0	0%	18	100%	0	0%	0	0%	18	100%	18	100%	0	0%	18	100%	0	0%
<i>Abbott</i>	18	18	100%		0%	18	100%		0%		0%	18	100%	18	100%		0%	18	100%		0%
Other Methods	3	3	100%		0%	3	100%		0%		0%		0%	3	100%		0%	3	100%		0%
Analyte Total	174	174	100%	0	0%	173	99%	1	1%	1	1%	170	98%	174	100%	0	0%	174	100%	0	0%

¹ All 3 laboratories using the Chiron RIBA confirmatory assay reported an equivocal result on sample #73.

HIV Antibody

		Participant Results/ Sample Number																				
		R = Reactive/ Positive; N = Non-Reactive/ Negative																				
Method	No. Labs	31 N				32 N				33 N				34 N				35 R				
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	
EIA	124	123	99%	1	1%	124	100%	0	0%	124	100%	0	0%	124	100%	0	0%	0	0%	124	100%	
	<i>Abbott</i>	65	64	98%	1	2%	65	100%		0%	65	100%		0%	65	100%		0%		0%	65	100%
	<i>bioMérieux</i>	16	16	100%		0%	16	100%		0%	16	100%		0%	16	100%		0%		0%	16	100%
	<i>Bio-Rad</i>	43	43	100%		0%	43	100%		0%	43	100%		0%	43	100%		0%		0%	43	100%
Rapid EIA	99	99	100%	0	0%	99	100%	0	0%	99	100%	0	0%	99	100%	0	0%	0	0%	99	100%	
	<i>Orasure</i>	99	99	100%		0%	99	100%		0%	99	100%		0%	99	100%		0%		0%	99	100%
Rapid Immunoassay	40	40	100%	0	0%	40	100%	0	0%	40	100%	0	0%	40	100%	0	0%	0	0%	40	100%	
	<i>Medmira</i>	21	21	100%		0%	21	100%		0%	21	100%		0%	21	100%		0%		0%	21	100%
	<i>Trinity</i>	16	16	100%		0%	16	100%		0%	16	100%		0%	16	100%		0%		0%	16	100%
	<i>Other</i>	3	3	100%		0%	3	100%		0%	3	100%		0%	3	100%		0%		0%	3	100%
Western Blot	45	44	98%	0	0%	45	100%	0	0%	45	100%	0	0%	44	98%	0	0%	0	0%	45	100%	
	<i>Bio-Rad</i> ¹	40	39	98%		0%	40	100%		0%	40	100%		0%	39	98%		0%		0%	40	100%
	<i>Other</i>	5	5	100%		0%	5	100%		0%	5	100%		0%	5	100%		0%		0%	5	100%
Other Methods	8	8	100%		0%	8	100%		0%	8	100%		0%	8	100%		0%		0%	8	100%	
Analyte Total	316	314	99%	1	0%	316	100%	0	0%	316	100%	0	0%	315	100%	0	0%	0	0%	316	100%	

¹ One laboratory reported an equivocal on #31 and one laboratory reported an equivocal on #34.

HIV p24 Antigen

		Participant Results/ Sample Number																				
		R = Reactive/ Positive; N = Non-Reactive/ Negative																				
Method	No. Labs	61 R				62 N				63 N				64 N				65 N				
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	
EIA	3	0	0%	3	100%	3	100%	0	0%	3	100%	0	0%	3	100%	0	0%	3	100%	0	0%	
	<i>Beckman Coulter</i>	3		0%	3	100%	3	100%		0%	3	100%		0%	3	100%		0%	3	100%		0%
Analyte Total	3	0	0%	3	100%	3	100%	0	0%	3	100%	0	0%	3	100%	0	0%	3	100%	0	0%	

HTLV Antibody

		Participant Results/ Sample Number																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative																			
Method	No. Labs	36 N				37 N				38 N				39 N				40 R			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
EIA	45	45	100%	0	0%	45	100%	0	0%	45	100%	0	0%	45	100%	0	0%	9	20%	35	78%
<i>Abbott</i>	31	31	100%		0%	31	100%		0%	31	100%		0%	31	100%		0%		0%	31	100%
<i>bioMérieux</i>	14	14	100%		0%	14	100%		0%	14	100%		0%	14	100%		0%	9	64%	4	29%
Other Methods	1	1	100%		0%	1	100%		0%	1	100%		0%	1	100%		0%		0%	1	100%
Analyte Total	46	46	100%	0	0%	46	100%	0	0%	46	100%	0	0%	46	100%	0	0%	9	20%	36	78%

¹ One laboratory reported an equivocal result on sample #40.

Infectious Mononucleosis

		Participant Results/ Sample Number																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative																			
Method	No. Labs	26 R				27 N				28 N				29 N				30 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
CICA	29	0	0%	29	100%	29	100%	0	0%	29	100%	0	0%	29	100%	0	0%	28	97%	1	3%
<i>Cardinal Health SP</i>	10		0%	10	100%	10	100%		0%	10	100%		0%	10	100%		0%	9	90%	1	10%
<i>Others</i>	19		0%	19	100%	19	100%		0%	19	100%		0%	19	100%		0%	19	100%		0%
Hemagglutination	44	0	0%	44	100%	44	100%	0	0%	44	100%	0	0%	44	100%	0	0%	44	100%	0	0%
<i>Fisher</i>	15		0%	15	100%	15	100%		0%	15	100%		0%	15	100%		0%	15	100%		0%
<i>Wampole/Zeus</i>	21		0%	21	100%	21	100%		0%	21	100%		0%	21	100%		0%	21	100%		0%
<i>Others</i>	8		0%	8	100%	8	100%		0%	8	100%		0%	8	100%		0%	8	100%		0%
Latex Agglutination	152	0	0%	152	100%	152	100%	0	0%	152	100%	0	0%	152	100%	0	0%	152	100%	0	0%
<i>Fisher</i>	53		0%	53	100%	53	100%		0%	53	100%		0%	53	100%		0%	53	100%		0%
<i>Remel</i>	22		0%	22	100%	22	100%		0%	22	100%		0%	22	100%		0%	22	100%		0%
<i>Wampole/Zeus</i>	54		0%	54	100%	54	100%		0%	54	100%		0%	54	100%		0%	54	100%		0%
<i>Others</i>	23		0%	23	100%	23	100%		0%	23	100%		0%	23	100%		0%	23	100%		0%
Solid Phase IA	59	0	0%	59	100%	59	100%	0	0%	59	100%	0	0%	59	100%	0	0%	59	100%	0	0%
<i>Seradyn</i>	24		0%	24	100%	24	100%		0%	24	100%		0%	24	100%		0%	24	100%		0%
<i>Wampole/Zeus</i>	27		0%	27	100%	27	100%		0%	27	100%		0%	27	100%		0%	27	100%		0%
<i>Others</i>	8		0%	8	100%	8	100%		0%	8	100%		0%	8	100%		0%	8	100%		0%
Other Methods	4		0%	4	100%	4	100%		0%	4	100%		0%	4	100%		0%	4	100%		0%
Analyte Total	288	0	0%	288	100%	288	100%	0	0%	288	100%	0	0%	288	100%	0	0%	287	100%	1	0%

Infectious Mononucleosis Latex Agglutination Procedures

The number of laboratories that reported titers are summarized for positive test sample 26. The dilution schemes laboratories used are represented by the letter A and B. Only methods with 10 or more laboratories reporting titers are listed in this table.

Method	No. Labs	Sample 26 Titers							
		A	2	4	8	16	32	64	128
Latex Agglutination	18	B	7	14	28	56			
				5	3	4	4	1	

Note: The number of labs reporting specific titers may not add up to the total number of labs for that system because some labs are not reporting endpoint titers.

Lyme Disease Antibody

Participant Results/ Sample Number																					
R = Reactive/ Positive; N = Non-Reactive/ Negative																					
Method	No. Labs	41 N				42 R				43 N				44 N				45 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
EIA	66	66	100%	0	0%	0	0%	66	100%	66	100%	0	0%	66	100%	0	0%	66	100%	0	0%
<i>Immunitics</i>	18	18	100%		0%		0%	18	100%	18	100%		0%	18	100%		0%	18	100%		0%
<i>Wampole /Zeus</i>	36	36	100%		0%		0%	36	100%	36	100%		0%	36	100%		0%	36	100%		0%
<i>Others</i>	12	12	100%		0%		0%	12	100%	12	100%		0%	12	100%		0%	12	100%		0%
ELFA	30	30	100%	0	0%	0	0%	29	97%	30	100%	0	0%	30	100%	0	0%	30	100%	0	0%
<i>bioMérieux</i> ¹	30	30	100%		0%		0%	29	97%	30	100%		0%	30	100%		0%	30	100%		0%
Other Methods	8	8	100%		0%	1	13%	7	88%	8	100%		0%	8	100%		0%	8	100%		0%
Analyte Total	104	104	100%	0	0%	1	1%	102	98%	104	100%	0	0%	104	100%	0	0%	104	100%	0	0%

¹ One laboratory reported a result of equivocal on sample #42

Lyme Western Blot IgG

		Participant Results/ Sample Number																																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative; E = Equivocal/ Indeterminate																																			
Method	No. Labs	41 N						42 R						43 N						44 N						45 N											
		N	%	E	%	R	%	N	%	E	%	R	%	N	%	E	%	R	%	N	%	E	%	R	%	N	%	E	%	R	%						
Western Blot - IgG	28	28	100%	0	0%	0	0%	0	0%	0	0%	28	100%	28	100%	0	0%	0	0%	28	100%	0	0%	0	0%	28	100%	0	0%	0	0%	28	100%	0	0%	0	0%
<i>MarDx</i>	26	26	100%		0%		0%		0%		0%	26	100%	26	100%		0%		0%	26	100%		0%		0%	26	100%		0%		0%	26	100%		0%		0%
<i>Other</i>	2	2	100%		0%		0%		0%		0%	2	100%	2	100%		0%		0%	2	100%		0%		0%	2	100%		0%		0%	2	100%		0%		0%
Other Methods	3	3	100%		0%		0%		0%		0%	3	100%	3	100%		0%		0%	3	100%		0%		0%	3	100%		0%		0%	3	100%		0%		0%
Analyte Total	31	31	100%	0	0%	0	0%	0	0%	0	0%	31	100%	31	100%	0	0%	0	0%	31	100%	0	0%	0	0%	31	100%	0	0%	0	0%	31	100%	0	0%	0	0%

Lyme Western Blot IgM

		Participant Results/ Sample Number																																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative; E = Equivocal/ Indeterminate																																			
Method	No. Labs	41 N						42 R*						43 N						44 N						45 N											
		N	%	E	%	R	%	N	%	E	%	R	%	N	%	E	%	R	%	N	%	E	%	R	%	N	%	E	%	R	%						
Western Blot - IgM	28	28	100%	0	0%	0	0%	12	43%	3	11%	13	46%	28	100%	0	0%	0	0%	28	100%	0	0%	0	0%	28	100%	0	0%	0	0%	28	100%	0	0%	0	0%
<i>MarDx</i>	26	26	100%		0%		0%	10	38%	3	12%	13	50%	26	100%		0%		0%	26	100%		0%		0%	26	100%		0%		0%	26	100%		0%		0%
<i>Other</i>	2	2	100%		0%		0%	2	100%		0%		0%	2	100%		0%		0%	2	100%		0%		0%	2	100%		0%		0%	2	100%		0%		0%
Other Methods	2	2	100%		0%		0%	1	50%		0%	1	50%	2	100%		0%		0%	2	100%		0%		0%	2	100%		0%		0%	2	100%		0%		0%
Analyte Total	30	30	100%	0	0%	0	0%	13	43%	3	10%	14	47%	30	100%	0	0%	0	0%	30	100%	0	0%	0	0%	30	100%	0	0%	0	0%	30	100%	0	0%	0	0%

* Test sample was not authenticated, because a consensus of 80% agreement was not reached. All participating laboratories received credit for this sample.

Rheumatoid Factor

		Participant Results/ Sample Number																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative																			
Method	No. Labs	26 N				27 N				28 R				29 N				30 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
EIA	12	12	100%	0	0%	12	100%	0	0%	0	0%	12	100%	12	100%	0	0%	12	100%	0	0%
<i>Others</i>	12	12	100%		0%	12	100%		0%		0%	12	100%	12	100%		0%	12	100%		0%
Latex Agglutination	123	121	98%	2	2%	123	100%	0	0%	0	0%	123	100%	123	100%	0	0%	123	100%	0	0%
<i>Becton Dickinson</i>	19	19	100%		0%	19	100%		0%		0%	19	100%	19	100%		0%	19	100%		0%
<i>Fisher</i>	48	48	100%		0%	48	100%		0%		0%	48	100%	48	100%		0%	48	100%		0%
<i>Seradyn</i>	12	12	100%		0%	12	100%		0%		0%	12	100%	12	100%		0%	12	100%		0%
<i>Wampole/Zeus</i>	12	10	83%	2	17%	12	100%		0%		0%	12	100%	12	100%		0%	12	100%		0%
<i>Others</i>	32	32	100%		0%	32	100%		0%		0%	32	100%	32	100%		0%	32	100%		0%
Nephelometry	41	41	100%	0	0%	41	100%	0	0%	0	0%	41	100%	41	100%	0	0%	41	100%	0	0%
<i>Beckman Coulter</i>	18	18	100%		0%	18	100%		0%		0%	18	100%	18	100%		0%	18	100%		0%
<i>Behring</i>	23	23	100%		0%	23	100%		0%		0%	23	100%	23	100%		0%	23	100%		0%
Turbidimetry	41	41	100%	0	0%	41	100%	0	0%	1	2%	40	98%	40	98%	1	2%	40	98%	1	2%
<i>Beckman Coulter</i>	15	15	100%		0%	15	100%		0%	1	7%	14	93%	15	100%		0%	14	93%	1	7%
<i>Roche</i>	23	23	100%		0%	23	100%		0%		0%	23	100%	22	96%	1	4%	23	100%		0%
<i>Others</i>	3	3	100%		0%	3	100%		0%		0%	3	100%	3	100%		0%	3	100%		0%
Other Methods	5	5	100%	0	0%	5	100%	0	0%	0	0%	5	100%	5	100%	0	0%	5	100%	0	0%
Analyte Total	222	220	99%	2	1%	222	100%	0	0%	1	0%	221	100%	221	100%	1	0%	221	100%	1	0%

Rheumatoid Factor Latex Agglutination Procedure

The number of laboratories that reported titers is listed for positive test sample 28. The dilution schemes laboratories used are represented by the letter A and B, testing systems with 10 or more laboratories reporting titers are listed in this table.

<i>Manufacturer</i>	No. Labs	A B	Sample 28 Titers					
			40 4	80 8	160 16	320 32	640 64	1280 128
<i>Fisher</i>	36	A B		2	8 13	5 5		
<i>Becton Dickenson</i>	15	A B	2	6	5	2		

Note: The number of labs reporting specific titers may not add up to the total number of labs for that system because some labs are not reporting endpoint titers.

Rheumatoid Factor

Results are summarized for positive test sample 28. The Mean values \pm S.D. are given where 10 or more laboratories reported quantitative results. Outlier values are omitted.

Method <i>Manufacturer</i>	No. Labs	IU/ml Sample 28
Nephelometry		
<i>Beckman Coulter IMMAGE</i>	15	300 \pm 14
Turbidimetry		
<i>Roche Diag. Cobas</i>	14	161 \pm 5.9

Rubella IgG Antibody

Method <i>Manufacturer</i>		Participant Results/ Sample Number																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative																			
		11 N				12 N				13 N				14 R				15 N			
No. Labs	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	
Chemiluminescence	68	68	100%	0	0%	68	100%	0	0%	68	100%	0	0%	0	0%	60	88%	68	100%	0	0%
<i>Bayer</i>	29	29	100%		0%	29	100%		0%	29	100%		0%		0%	29	100%	29	100%		0%
<i>Beckman</i> ¹	15	15	100%		0%	15	100%		0%	15	100%		0%		0%	7	47%	15	100%		0%
<i>Diagnostic Products</i>	24	24	100%		0%	24	100%		0%	24	100%		0%		0%	24	100%	24	100%		0%
EIA	58	58	100%	0	0%	58	100%	0	0%	58	100%	0	0%	0	0%	56	97%	58	100%	0	0%
<i>Abbott</i> ²	24	24	100%		0%	24	100%		0%	24	100%		0%		0%	23	96%	24	100%		0%
<i>Diamedix</i>	12	12	100%		0%	12	100%		0%	12	100%		0%		0%	12	100%	12	100%		0%
<i>Wampole/Zeus</i>	11	11	100%		0%	11	100%		0%	11	100%		0%		0%	11	100%	11	100%		0%
<i>Others</i> ³	11	11	100%		0%	11	100%		0%	11	100%		0%		0%	10	91%	11	100%		0%
ELFA	33	33	100%	0	0%	33	100%	0	0%	33	100%	0	0%	0	0%	33	100%	33	100%	0	0%
<i>bioMérieux Vidas</i>	33	33	100%		0%	33	100%		0%	33	100%		0%		0%	33	100%	33	100%		0%
Latex Agglutination	37	37	100%	0	0%	37	100%	0	0%	37	100%	0	0%	0	0%	37	100%	37	100%	0	0%
<i>Fisher</i>	20	20	100%		0%	20	100%		0%	20	100%		0%		0%	20	100%	20	100%		0%
<i>Others</i>	17	17	100%		0%	17	100%		0%	17	100%		0%		0%	17	100%	17	100%		0%
Other Methods	7	7	100%		0%	7	100%		0%	7	100%		0%		0%	7	100%	7	100%		0%
Analyte Total	203	203	100%	0	0%	203	100%	0	0%	203	100%	0	0%	0	0%	193	95%	203	100%	0	0%

¹ Eight laboratories reported a result of equivocal on sample #14.

² One laboratory reported a result of equivocal on sample #14.

³ One laboratory reported a result of equivocal on sample #14.

Rubella IgG Antibody

Results are summarized for positive test sample 14. The Mean values \pm S.D. are given where 10 or more laboratories reported quantitative results. Outlier values are omitted.

Method	No.	Unit	Sample 14
<i>Manufacturer</i>	<i>Labs</i>		
Chemiluminescence			
<i>Bayer</i>	22	IU/ml	38 \pm 3.9
<i>Diagnostic Products</i>	20	IU/ml	14 \pm 1.8

Rubella IgM Specific

		Participant Results/ Sample Number																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative																			
Method <i>Manufacturer</i>	No. Labs	56 N				57 N				58 N				59 N				60 R			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
EIA	11	11	100%		0%	11	100%		0%	11	100%		0%	11	100%		0%		0%	11	100%
Chemiluminescence	10	9	90%	1	10%	9	90%	1	10%	9	90%	1	10%	9	90%	1	10%		0%	10	100%
Analyte Total	21	20	95%	1	5%	20	95%	1	5%	20	95%	1	5%	20	95%	1	5%	0	0%	21	100%

Syphilis - Reagin Antibody

		Participant Results/ Sample Number																			
		R = Reactive/ Positive; N = Non-Reactive/ Negative																			
Method <i>Manufacturer</i>	No. Labs	1 R				2 R				3 R				4 N				5 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
RPR	275	0	0%	275	100%	0	0%	275	100%	16	6%	258	94%	275	100%	0	0%	275	100%	0	0%
<i>ASI</i>	40		0%	40	100%		0%	40	100%		0%	40	100%	40	100%		0%	40	100%		0%
<i>Becton Dickenson</i>	137		0%	137	100%		0%	137	100%	3	2%	134	98%	137	100%		0%	137	100%		0%
<i>Fisher</i>	48		0%	48	100%		0%	48	100%	4	8%	44	92%	48	100%		0%	48	100%		0%
<i>True Medix</i> ¹	17		0%	17	100%		0%	17	100%	1	6%	15	88%	17	100%		0%	17	100%		0%
<i>Wampole/Zeus</i>	20		0%	20	100%		0%	20	100%	2	10%	18	90%	20	100%		0%	20	100%		0%
<i>Others</i>	13		0%	13	100%		0%	13	100%	6	46%	7	54%	13	100%		0%	13	100%		0%
Other Methods	1		0%	1	100%		0%	1	100%		0%	1	100%	1	100%		0%	1	100%		0%
Analyte Total	276	0	0%	276	100%	0	0%	276	100%	16	6%	259	94%	276	100%	0	0%	276	100%	0	0%

1 One laboratory reported a result of equivocal/indeterminate on sample #3.

Syphilis - Reagin Antibody RPR Procedures

The number of laboratories that reported titers is listed for positive test samples 1, 2 and 3 for the RPR procedure. Only testing systems with 10 or more laboratories reporting titers are listed in this table.

Method Manufacturer	No. Labs	Sample 1 Titers						Sample 2 Titers						Sample 3 Titers					
		1	2	4	8	16	32	1	2	4	8	16	32	1	2	4	8	16	32
ASI	28			3	23	2			8	20				12	13	3			
Becton Dickenson	124			4	96	24			20	94	10			28	45	14	21	12	
Fisher	48			8	35	5		1	14	30	3			14	23	5	1		1
True Medix	17		1	5	7	4		3	4	10				8	6		1		
Wampole/ Zeus	20		1	3	15	1			9	9	2			11	2	2	1	2	

Note: The number of labs reporting specific titers may not add up to the total number of labs for that system because some labs are not reporting endpoint titers.

Syphilis - Treponemal Antibody

Participant Results/ Sample Number																					
R = Reactive/ Positive; N = Non-Reactive/ Negative																					
Method	No. Labs	1 R				2 R				3 R				4 N				5 N			
		N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%	N	%	R	%
EIA	9	0	0%	9	100%	0	0%	9	100%	1	11%	8	89%	9	100%	0	0%	9	100%	0	0%
<i>Other ¹</i>	9		0%	9	100%		0%	9	100%	1	11%	8	89%	9	100%		0%	9	100%		0%
Gel. Part. Agglut.	34	0	0%	34	100%	0	0%	34	100%	0	0%	34	100%	34	100%	0	0%	34	100%	0	0%
<i>Fujirebio</i>	34		0%	34	100%		0%	34	100%		0%	34	100%	34	100%		0%	34	100%		0%
IFA	27	0	0%	27	100%	0	0%	27	100%	0	0%	27	100%	27	100%	0	0%	27	100%	0	0%
<i>Wampole/Zeus</i>	27		0%	27	100%		0%	27	100%		0%	27	100%	27	100%		0%	27	100%		0%
MHA	10	0	0%	10	100%	0	0%	10	100%	0	0%	10	100%	10	100%	0	0%	10	100%	0	0%
<i>Olympus</i>	10		0%	10	100%		0%	10	100%		0%	10	100%	10	100%		0%	10	100%		0%
Other Methods ²	7		0%	7	100%		0%	7	100%	1	14%	6	86%	7	100%		0%	7	100%		0%
Analyte Total	87	0	0%	87	100%	0	0%	87	100%	2	2%	85	98%	87	100%	0	0%	87	100%	0	0%

AAT, C'3, and C'4

The Mean mg/dl \pm S.D. is given where 10 or more laboratories reported values. Outlier values are omitted.

Analytes	No.	Sample NO.				
		Labs	76	77	78	79
Alpha-1-Antitrypsin						
Nephelometry/Beckman Coulter IMMAGE	10	< 10	148 \pm 8.4	< 10	175 \pm 7.6	192 \pm 12
Nephelometry/Behring Nephelometer	19	< 16	207 \pm 7.6	< 16	259 \pm 9.7	208 \pm 1
Nephelometry/ Total	30	< 16	185 \pm 29	< 16	230 \pm 44	202 \pm 13
Turbidimetry/ Total	6	< 36	162 \pm 7.5	< 36	191 \pm 9.6	181 \pm 5.8
Complement C'3						
Nephelometry/Beckman Coulter IMMAGE	18	40 \pm 1.0	331 \pm 15	31 \pm 1.3	236 \pm 9.4	119 \pm 5.1
Nephelometry/Behring Nephelometer	18	42 \pm 3.0	372 \pm 28	33 \pm 0.9	243 \pm 18	131 \pm 10
Turbidimetry/Roche Cobas Integra	11	42 \pm 2.4	374 \pm 16	33 \pm 2.0	239 \pm 8.8	127 \pm 1.9
Nephelometry/ Total	51	41 \pm 2.1	351 \pm 28	32 \pm 2.0	235 \pm 11	125 \pm 9.3
Turbidimetry/ Total	44	42 \pm 3.7	372 \pm 27	34 \pm 3.5	242 \pm 16	124 \pm 7.0
Complement C'4						
Nephelometry/Beckman Coulter IMMAGE	18	4.7 \pm 0.3	42 \pm 1.9	3.7 \pm 0.3	121 \pm 3.7	36 \pm 1.7
Nephelometry/Behring Nephelometer	16	4.1 \pm 0.2	37 \pm 1.6	3.2 \pm 0.3	114 \pm 8.2	35 \pm 1.6
Nephelometry/Behring BN Prospec	11	4.5 \pm 0.2	37 \pm 1.1	3.7 \pm 0.2	108 \pm 2.2	35 \pm 1.9
Turbidimetry/Roche Cobas Integra	10	< 6	40 \pm 1.0	< 6	111 \pm 5.4	35 \pm 1.1
Nephelometry/ Total	52	< 10	39 \pm 2.8	< 10	114 \pm 9.5	35 \pm 2.1
Turbidimetry/ Total	41	< 10	37 \pm 4.2	< 10	107 \pm 13	32 \pm 3.4

IgA, IgE, IgG, and IgM

The Mean mg/dl (IU/ml for IgE) \pm S.D. is given for IgA, IgE, and IgM and Mean mg/dl \pm 25% is given for IgG where 10 or more laboratories reported values. Outlier values are omitted.

Analytes (Unit)	No.	Sample NO.					
		Labs	81	82	83	84	85
Immunoglobulin A (mg/dl)							
Nephelometry/Beckman Coulter IMMAGE	20		113 \pm 5.1	47 \pm 2.4	314 \pm 13	619 \pm 38	181 \pm 9.5
Nephelometry/Behring Nephelometer	19		117 \pm 9.3	49 \pm 1.9	302 \pm 16	669 \pm 69	209 \pm 28
Nephelometry/Behring BN Prospec	12		113 \pm 7.9	49 \pm 1.5	289 \pm 6.9	715 \pm 68	201 \pm 26
Nephelometry/ Total	62		114 \pm 7.4	48 \pm 2.5	304 \pm 17	647 \pm 70	183 \pm 8.0
Turbidimetry/ Total	51		104 \pm 10	47 \pm 5.8	291 \pm 11	559 \pm 62	163 \pm 11
Immunoglobulin E (IU/ml)							
Chemiluminescence/Bayer	12		740 \pm 71	28 \pm 1.6	6.4 \pm 0.9	467 \pm 25	145 \pm 5.6
Chemiluminescence/Diag. Prod. Co.	33		680 \pm 58	29 \pm 2.0	8.0 \pm 0.7	388 \pm 33	151 \pm 11
Chemiluminescence/ Total	49		699 \pm 73	28 \pm 2.0	7.7 \pm 0.9	405 \pm 50	149 \pm 11
FEIA/ Total	15		677 \pm 65	29 \pm 1.7	11 \pm 0.8	455 \pm 43	161 \pm 13
Nephelometry/ Total	13		668 \pm 39	27 \pm 2.0	8.8 \pm 1.4	394 \pm 28	135 \pm 8.4
Immunoglobulin G (mg/dl)							
Nephelometry/Beckman Coulter IMMAGE	20		641 \pm 24	251 \pm 11	1118 \pm 37	2439 \pm 84	894 \pm 25
Nephelometry/Behring Nephelometer	20		691 \pm 38	260 \pm 14	1155 \pm 54	3060 \pm 179	995 \pm 28
Nephelometry/Behring BN Prospec	13		686 \pm 25	261 \pm 6.8	1155 \pm 11	3009 \pm 90	980 \pm 28
Turbidimetry/Roche Cobas Integra	13		611 \pm 26	232 \pm 5.0	1031 \pm 42	2472 \pm 94	854 \pm 13
Nephelometry/ Total	63		669 \pm 39	255 \pm 15	1132 \pm 49	2759 \pm 336	942 \pm 57
Turbidimetry/ Total	49		618 \pm 31	240 \pm 16	1055 \pm 54	2448 \pm 226	855 \pm 38
Immunoglobulin M (mg/dl)							
Nephelometry/Beckman Coulter IMMAGE	20		136 \pm 7.1	25 \pm 1.1	116 \pm 6.5	215 \pm 10	368 \pm 14
Nephelometry/Behring Nephelometer	18		135 \pm 4.2	26 \pm 1.6	110 \pm 3.9	297 \pm 13	436 \pm 32
Nephelometry/Behring BN Prospec	13		132 \pm 3.2	26 \pm 1.5	110 \pm 3.0	279 \pm 6.9	418 \pm 28
Turbidimetry/Roche Cobas Integra	13		137 \pm 3.2	21 \pm 2.6	112 \pm 4.0	170 \pm 5.3	452 \pm 8.5
Nephelometry/ Total	61		135 \pm 5.7	26 \pm 1.6	114 \pm 6.5	260 \pm 39	400 \pm 41
Turbidimetry/ Total	48		132 \pm 6.5	26 \pm 4.1	110 \pm 4.7	197 \pm 31	403 \pm 40

Acceptable Response (January 17, 2007 PT Event)
Quantitative Tests Results (Acceptable Range)

Analytes	Sample NO.				
Method/ Manufacture					
Alpha-1-Antitrypsin	76	77	78	79	80
Nephelometry/Beckman Coulter Immage	< 10	122 - 173	< 10	152 - 199	156 - 228
Nephelometry/Dade Behring Neph.	< 16	183 - 230	< 16	230 - 289	175 - 241
Nephelometry/ Total	< 16	96 - 274	< 16	99 - 362	162 - 242
Turbidimetry/ Total	< 36	139 - 185	< 36	161 - 220	163 - 199
Complement C'3	76	77	78	79	80
Nephelometry/Beckman Coulter Immage	37 - 44	287 - 375	27 - 36	207 - 264	103 - 135
Nephelometry/Dade Behring Neph.	32 - 51	287 - 457	30 - 37	189 - 297	100 - 163
Turbidimetry/Roche Cobas Integra	34 - 49	326 - 422	26 - 39	213 - 266	120 - 133
Nephelometry/ Total	34 - 47	265 - 436	26 - 39	201 - 269	96 - 153
Turbidimetry/ Total	30 - 54	291 - 454	23 - 44	193 - 291	102 - 145
Complement C'4	76	77	78	79	80
Nephelometry/Beckman Coulter Immage	3 - 6	35 - 48	2 - 5	110 - 133	30 - 42
Nephelometry/Dade Behring Neph.	3 - 5	32 - 42	2 - 5	89 - 139	30 - 40
Nephelometry/Dade Behring BN P.	3 - 6	33 - 41	2 - 5	101 - 116	29 - 41
Turbidimetry/Roche Cobas Integra	< 6	36 - 43	< 6	95 - 128	31 - 39
Nephelometry/ Total	< 10	30 - 47	< 10	85 - 142	28 - 42
Turbidimetry/ Total	< 10	24 - 50	< 10	68 - 146	22 - 44
Immunoglobulin A	81	82	83	84	85
Nephelometry/Beckman Coulter Immage	97 - 127	39 - 55	275 - 353	506 - 734	152 - 210
Nephelometry/Dade Behring Neph .	88 - 145	43 - 55	252 - 351	463 - 875	123 - 294
Nephelometry/Dade Behring BN P.	89 - 138	44 - 54	268 - 311	515 - 916	123 - 280
Nephelometry/ Total	92 - 137	40 - 56	252 - 355	436 - 859	158 - 207
Turbidimetry/ Total	73 - 137	29 - 65	258 - 324	373 - 747	130 - 197
Immunoglobulin E	81	82	83	84	85
Chemiluminescence/Bayer Advia Centaur	527 - 952	23 - 34	3 - 10	391 - 543	128 - 162
Chemiluminescence/Diag.Prod. Immulite	505 - 856	22 - 35	5 - 10	288 - 488	117 - 186
Chemiluminescence/ Total	478 - 919	22 - 35	4 - 11	254 - 556	115 - 182
FEIA/ Total	482 - 873	24 - 34	8 - 14	325 - 585	121 - 201
Nephelometry/ Total	549 - 787	20 - 33	4 - 14	311 - 478	110 - 161
Immunoglobulin G	81	82	83	84	85
Nephelometry/Beckman Coulter Immage	480 - 802	187 - 314	838 - 1399	1829 - 3050	670 - 1118
Nephelometry/Dade Behring Neph .	518 - 864	194 - 325	866 - 1444	2294 - 3825	746 - 1244
Nephelometry/Dade Behring BN P.	514 - 858	195 - 327	866 - 1445	2256 - 3762	735 - 1225
Turbidimetry/Roche Cobas Integra	458 - 764	174 - 291	773 - 1289	1854 - 3091	640 - 1068
Nephelometry/ Total	502 - 837	191 - 320	849 - 1416	2069 - 3450	707 - 1179
Turbidimetry/ Total	463 - 773	179 - 300	791 - 1319	1836 - 3061	640 - 1069
Immunoglobulin M	81	82	83	84	85
Nephelometry/Beckman Coulter Immage	115 - 158	22 - 29	96 - 136	183 - 246	326 - 411
Nephelometry/Dade Behring Neph .	122 - 148	20 - 31	98 - 122	256 - 338	341 - 531
Nephelometry/Dade Behring BN P.	122 - 143	21 - 31	101 - 120	259 - 301	333 - 503
Turbidimetry/Roche Cobas Integra	127 - 147	13 - 30	99 - 124	154 - 187	426 - 477
Nephelometry/ Total	118 - 152	20 - 31	94 - 134	143 - 378	278 - 523
Turbidimetry/ Total	112 - 152	13 - 38	96 - 125	105 - 289	282 - 524

Acceptable Response (January 17, 2007 PT Event)
Qualitative / Quantitative Tests Results

Analytes	Sample NO.				
	1	2	3	4	5
Syphilis - Reagin Ab	R	R	R	N	N
<i>RPR Titer</i>	4 - 16	1 - 8	1 - 16		
Syphilis - Treponemal	R	R	R	N	N
	6	7	8	9	10
HBcAb	R	R	N	N	N
HBsAg	R	N	N	N	N
	11	12	13	14	15
CMV	N	N	N	R	N
Rubella Ab	N	N	N	R	N
	16	17	18	19	20
ASO	N	N	R	N	N
<i>Latex Agglutination as IU/ml</i>			100 - 1600		
<i>Nephelometry IU/ml</i>			216 - 1118		
	26	27	28	29	30
Infectious Mono.	R	N	N	N	N
<i>Latex Agglutination Titer</i>	4 - 64				
Rheumatoid Factor	N	N	R	N	N
<i>Latex Agglutination Titer</i>			4 - 64		
<i>Latex Agglutination as IU/ml</i>			40 - 640		
	31	32	33	34	35
HIV Ab Screening/Confirmation	N	N	N	N	R
	36	37	38	39	40
HTLV 1 Ab	N	N	N	N	R
	41	42	43	44	45
LYME Disease Ab	N	R	N	N	N
LYME Disease Ab WB IgG	N	R	N	N	N
LYME Disease Ab WB IgM	N	R *	N	N	N
	46	47	48	49	50
ANA	N	N	N	R	N
<i>IFA Titer</i>				80 - 1280	
	56	57	58	59	60
Rubella IgM	N	N	N	N	R
	61	62	63	64	65
HIV p24 Ag	R	N	N	N	N
	66	67	68	69	70
HBeAg	N	R	N	N	N
	71	72	73	74	75
Hepatitis C Ab	N	N	R	N	N

Note: R = Reactive/ Positive; I = Indeterminate; N = Non-Reactive/ Negative

* Test sample was not authenticated, because a consensus of 80% agreement was not reached. All participating laboratories received credit for this sample.